Summary of the Conference Call for Boteng Co., Ltd. Company Overview - The conference call pertains to Boteng Co., Ltd., which has released its 2024 annual report and ESG report on March 29, 2024 [1] Financial Performance - In 2024, the company achieved revenue of 3.01 billion RMB, a decline from 3.67 billion RMB in 2023, primarily due to the impact of large orders delivered in 2023 [2] - The company reported a net loss attributable to shareholders of 288 million RMB, marking its first loss since going public [2] - Excluding the impact of large orders, the company's revenue actually increased by 14% year-over-year [3] - The company's gross margin showed an upward trend in 2024, although new business segments had lower margins due to being in the cultivation phase [4] Business Segments - The chemical segment, when excluding large orders, saw a revenue increase of 13% in 2024 [3] - New business segments, including nucleic acid macromolecules and ADCs, experienced a 35% increase [3] - The company’s expenses were reduced by approximately 20% compared to previous years due to cost-cutting measures [5] Regional Performance - Revenue in the U.S. region declined due to a one-time impact, while Europe and Asia-Pacific regions showed growth [4] - The Asia-Pacific region achieved a growth rate of 35% [4] Strategic Initiatives - The company is undergoing a strategic transformation, focusing on enhancing customer satisfaction, which scored 9.2 out of 10 [7] - The company has made significant progress in cost reduction and efficiency improvements, with a global integrated marketing organization established [8] - The company has initiated a transformation in core business processes, improving order-to-cash cycles [9] New Business Development - The small molecule API segment reported revenue exceeding 500 million RMB, with a project count increase of 25 projects year-over-year [10] - The company has made strides in gene and cell therapy projects, achieving significant milestones in R&D and clinical trials [12] - The company has established new production capabilities in Shanghai, enhancing service capacity [13] Global Expansion - The company is focusing on global expansion, particularly in the U.S. and Europe, with revenue growth of 9% in the U.S. [13] - New capabilities in GNP and high-potency APIs have been developed to meet customer demands [13] Future Outlook - The company plans to enhance management capabilities in overseas subsidiaries and continue to improve operational efficiency [16] - The focus will be on providing customized global solutions to meet customer needs in a changing environment [16] Conclusion - Overall, Boteng Co., Ltd. is navigating a challenging environment with strategic initiatives aimed at cost reduction, efficiency improvement, and global expansion while addressing the impacts of previous large orders and market conditions [2][5][16]

一位推动国有企业向市场化、现代化、国际化方向变革的企业家。 文丨曾梦龙 编辑丨钱杨 在 35 年的职业生涯中，宁高宁扮演最多的角色是 "董事长"。他不仅担任过四家世界 500 强企业的董事长——华润、中粮、中国中化、中国化工，也担任过集 团旗下公司的董事长，如华润雪花啤酒、华润置地、华润电力，还有并购公司的董事长，如蒙牛、尼德拉（Nidera）、先正达（Syngenta）。 但他不喜欢强调 "董事长" 的身份。作为央企领导人，他有着官员级别，如果强调 "董事长"，企业所有人都会围着他转，在哪儿他都是最大。这样不对，会损 害组织的创新与活力，不利于组织发展。 宁高宁自豪的影像，一次是和中化同事合影，大家没注意到他没来就拍了。后来等他来了补拍，自己只是站在侧面的背后招手，粗看根本找不到他；另一次是 培训中粮员工，因为腰疼蹲不下去，他就跪在地上，在白板上接着写字。 2004 年，宁高宁调任为中粮董事长，开启了中粮 "全产业链" 的战略转型。他并购了荷兰的尼德拉和瑞士的来宝农业。这两家公司资产超过 200 亿美元，业务 遍布全球，让中粮走向国际化。2016 年，宁高宁又被委以重任，成为中化集团董事长，主导了中化 "科 ...